The hepatitis B vaccine is one of the most potent immunizations, usually providing decades of protection against the deadly liver virus. But in about 10% of people it doesn’t work, and in 2020, Amy Huei-Yi Lee, a systems biologist at Simon Fraser University, and her colleagues set out to determine whether they could predict who would benefit. The scientists found that data on recipients’ immune systems such as the abundance of certain proteins and the activity patterns of a few genes foretold whether they would generate defenses against the virus. “We got a sense of what factors drive the vaccine response and what [doesn’t],” Lee says.
Trending
- NEMA launches 2026 national disaster preparedness campaign
- Lagos to establish cybersecurity operations centre
- Nigeria becomes China’s largest engineering contracting market
- Kano pilgrims board warns against taking kolanut to Saudi Arabia
- L-PRES to scale NVRI vaccine production from 150m to 850m doses
- Adamawa warns against farming, building on waterways ahead of 2026 rains
- Philanthropist pledges solar power system to Anambra teaching hospital
- Nigerian army apprehends 5 railway vandals in Kaduna
